Valérie Delecroix

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography

Caroline Rousseau, Anne Devillers, Christine Sagan et al. · Journal of Clinical Oncology · 2006 · 312 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis

Pascal Jézéquel, L. Campion, M-P Joalland et al. · British Journal of Cancer · 2004 · 56 citations · Full text

Medicine, Molecular Genetics, Oncology +16

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study

F. Joly, Djihane Ahmed-Lecheheb, Elsa Kalbacher et al. · Annals of Oncology · 2019 · 55 citations

Medicine, Gynecology, Oncology +10